Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 267

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 267
---
| Receipt of a short-term loan and issuance of warrants (Note 5)              |     |                    |    325 |   |     |      |      - |   |
| Net cash provided by financing activities                                   |     |                    |    325 |   |     |      |      - |   |
| Net change in cash and cash equivalents                                     |     |                    |   (895 | ) |     |      | (1,504 | ) |
| Cash and cash equivalents at the beginning of the period                    |     |                    |  1,240 |   |     |      |  2,744 |   |
| Cash and cash equivalents at the end of the year                            |     | $                  |    345 |   |     | $    |  1,240 |   |
| Non-cash financing activities:                                              |     |                    |        |   |     |      |        |   |
| 2021 Notes conversion into preferred D-2 shares                             |     | $                  |  1,086 |   |     | $    |      - |   |

<div align='center'>The accompanying notes are an integral part of
the financial statements.

F-21</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1:- | GENERAL |

| a. | Regentis Biomaterials Ltd.                                                                                                                
 (the “Company”) commenced operations in September 2004. The Company develops innovative tissue repair solutions that                      
 seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic           
 treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is a          
 unique hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen. The Company’s lead product candidate is                
 GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular 
 knee cartilage.                                                                                                                           |

| b. | Transaction with OceanTech Corp. |

On May 2, 2023, OceanTech Acquisitions
I Corp., a Delaware corporation (“OceanTech”), R.B. Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of
OceanTech (“Merger Sub